pharmaceutical investing Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia
pharmaceutical investing Moleculin’s Breakthrough Discovery of a New Molecule for Cancer Treatment Advances to Development Agreement with the University of Iowa
pharmaceutical investing Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial
pharmaceutical investing Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials
pharmaceutical investing Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery
Moleculin Announces Collaboration with Emory University to Develop Novel Treatment of Pediatric Brain Cancer
Element79 Gold Corp Announces Corporate Update and Strategic Leadership Changes With Focus On Accelerating Nevada Asset Development
